$ACUR
ACURA PHARMACEUTICALS, INC

2013 Q2 Form 10-Q Financial Statement

#000114420413042470 Filed on August 01, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $1.000K $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin 0.0%
Selling, General & Admin $1.975M $1.270M
YoY Change 55.51% -26.59%
% of Gross Profit
Research & Development $805.0K $919.0K
YoY Change -12.4% -19.39%
% of Gross Profit
Depreciation & Amortization $40.00K $30.00K
YoY Change 33.33% -25.0%
% of Gross Profit
Operating Expenses $3.141M $2.189M
YoY Change 43.49% -23.73%
Operating Profit -$3.140M -$2.189M
YoY Change 43.44%
Interest Expense $0.00 $10.00K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $64.00K $10.00K
YoY Change 540.0% 0.0%
Pretax Income -$3.076M -$2.179M
YoY Change 41.17% -112.54%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.076M -$2.179M
YoY Change 41.17% -112.8%
Net Earnings / Revenue -307600.0%
Basic Earnings Per Share -$0.07 -$0.05
Diluted Earnings Per Share -$0.07 -$0.05
COMMON SHARES
Basic Shares Outstanding 47.23M shares 47.52K shares
Diluted Shares Outstanding 47.23M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.47M $31.16M
YoY Change -37.52% -21.11%
Cash & Equivalents $584.0K $31.16M
Short-Term Investments $18.88M
Other Short-Term Assets $530.0K $430.0K
YoY Change 23.26% -23.21%
Inventory $400.0K
Prepaid Expenses
Receivables $10.00K
Other Receivables $130.0K
Total Short-Term Assets $20.49M $31.75M
YoY Change -35.46% -20.74%
LONG-TERM ASSETS
Property, Plant & Equipment $1.006M $1.090M
YoY Change -7.71% 5.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K
YoY Change
Total Long-Term Assets $1.014M $1.090M
YoY Change -6.97% 4.81%
TOTAL ASSETS
Total Short-Term Assets $20.49M $31.75M
Total Long-Term Assets $1.014M $1.090M
Total Assets $21.51M $32.84M
YoY Change -34.52% -20.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $328.0K $70.00K
YoY Change 368.57%
Accrued Expenses $675.0K $820.0K
YoY Change -17.68% -13.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.076M $890.0K
YoY Change 20.9% -27.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.00K
YoY Change
Total Long-Term Liabilities $10.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.076M $890.0K
Total Long-Term Liabilities $10.00K $0.00
Total Liabilities $1.081M $890.0K
YoY Change 21.46% -27.64%
SHAREHOLDERS EQUITY
Retained Earnings -$342.5M
YoY Change
Common Stock $363.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.42M $31.94M
YoY Change
Total Liabilities & Shareholders Equity $21.51M $32.84M
YoY Change -34.52% -20.1%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$3.076M -$2.179M
YoY Change 41.17% -112.8%
Depreciation, Depletion And Amortization $40.00K $30.00K
YoY Change 33.33% -25.0%
Cash From Operating Activities -$4.080M -$2.000M
YoY Change 104.0% -111.36%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$40.00K
YoY Change -50.0% 300.0%
Acquisitions
YoY Change
Other Investing Activities $970.0K
YoY Change
Cash From Investing Activities $950.0K -$40.00K
YoY Change -2475.0% 300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K -10.00K
YoY Change -2600.0% -103.57%
NET CHANGE
Cash From Operating Activities -4.080M -2.000M
Cash From Investing Activities 950.0K -40.00K
Cash From Financing Activities 250.0K -10.00K
Net Change In Cash -2.880M -2.050M
YoY Change 40.49% -111.47%
FREE CASH FLOW
Cash From Operating Activities -$4.080M -$2.000M
Capital Expenditures -$20.00K -$40.00K
Free Cash Flow -$4.060M -$1.960M
YoY Change 107.14% -111.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
-100000 USD
CY2013Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
19000000 USD
CY2013Q2 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
800000 USD
CY2012Q4 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
200000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
61000 USD
CY2013Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
400000 USD
CY2013Q2 us-gaap Inventory Net
InventoryNet
400000 USD
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
145000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
55000 USD
CY2013Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
309000 USD
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
216000 USD
CY2013Q2 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
11000 USD
CY2012Q4 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
5000 USD
CY2013Q2 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
19000 USD
CY2012Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
20000 USD
CY2013Q2 acur Manufacturing Services Costs
ManufacturingServicesCosts
72000 USD
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
114000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75000 USD
CY2012Q4 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
21000 USD
CY2012Q4 acur Manufacturing Services Costs
ManufacturingServicesCosts
21000 USD
CY2013Q2 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
5000 USD
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
315000 USD
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
424000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0186 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.14 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.14 pure
acur Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedForfeitures
0.0 pure
acur Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedForfeitures
0.0 pure
CY2013Q2 acur Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
August 2014
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1900000 shares
CY2013Q2 acur Exercise Price Of Warrants
ExercisePriceOfWarrants
3.40
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5198 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
46399 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
45863 shares
CY2013Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
829 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47215 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
829 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1658 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1658 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47228 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47521 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47519 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13000000 USD
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
46386 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
45861 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
584000 USD
CY2013Q2 acur Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5000 USD
CY2012Q4 acur Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
0 USD
us-gaap Royalty Revenue
RoyaltyRevenue
5000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
0 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
919000 USD
us-gaap Revenues
Revenues
5000 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47215 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47521 shares
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
805000 USD
CY2013Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2336000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 USD
CY2013Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
71000 USD
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
61000 USD
CY2013Q2 us-gaap Marketable Securities
MarketableSecurities
18884000 USD
CY2013Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
8000 USD
CY2013Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
127000 USD
CY2013Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
361000 USD
CY2013Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
478000 USD
CY2013Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
49000 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
20491000 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1006000 USD
CY2013Q2 us-gaap Other Assets
OtherAssets
8000 USD
CY2013Q2 us-gaap Assets
Assets
21505000 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
328000 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
675000 USD
CY2013Q2 us-gaap Deferred Revenue
DeferredRevenue
61000 USD
CY2013Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12000 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1076000 USD
CY2013Q2 us-gaap Other Liabilities
OtherLiabilities
5000 USD
CY2013Q2 us-gaap Liabilities
Liabilities
1081000 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
465000 USD
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
362583000 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-342505000 USD
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-119000 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
20424000 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21505000 USD
CY2013Q2 us-gaap Royalty Revenue
RoyaltyRevenue
1000 USD
CY2013Q2 us-gaap Revenues
Revenues
1000 USD
acur Patents Expiration Year
PatentsExpirationYear
2025
CY2012Q2 us-gaap Revenues
Revenues
0 USD
CY2012Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1270000 USD
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
3141000 USD
CY2012Q2 us-gaap Costs And Expenses
CostsAndExpenses
2189000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3140000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2189000 USD
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000 USD
acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
8000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7294000 USD
CY2012Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
11000 USD
CY2013Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-7000 USD
CY2012Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3076000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2179000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-3076000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-2179000 USD
CY2013Q2 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-131000 USD
CY2012Q2 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
0 USD
CY2013Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-131000 USD
CY2012Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3207000 USD
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2179000 USD
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47228 shares
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2831000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1822000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4558000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2711000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7389000 USD
us-gaap Costs And Expenses
CostsAndExpenses
4533000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7384000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4533000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
81000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
22000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
9000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
64000 USD
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
90000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4512000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-7294000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4512000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-79000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47215 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47519 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47519 shares
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47228 shares
us-gaap Share Based Compensation
ShareBasedCompensation
848000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
630000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 USD
acur Payment Of Royalty Maximum Contractual Term
PaymentOfRoyaltyMaximumContractualTerm
P45D
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
100000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000 USD
acur Issuance Of Common Stock Value Under Market Offerings
IssuanceOfCommonStockValueUnderMarketOfferings
243000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
69000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
630000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
64000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
91000 USD
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
0 USD
us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
532000 USD
us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
0 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-43000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
207000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
143000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
49000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-666000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
262000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
347000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
61000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7398000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3379000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7612000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8604000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
110000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
969000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-110000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
716000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1046000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-463000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1037000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6892000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4526000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35685000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31159000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
43000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
-251000 USD
acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
0 USD
acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
390000 USD
acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
0 USD
acur Percentage Of Royalty Deduct To Settle Third Party Claim
PercentageOfRoyaltyDeductToSettleThirdPartyClaim
0.5 pure
acur Percentage Of Royalty Of Royalty Payable Minimum
PercentageOfRoyaltyOfRoyaltyPayableMinimum
0.8 pure
acur Research And Development Contingent Consideration Payment Sales Milestone Payment Description
ResearchAndDevelopmentContingentConsiderationPaymentSalesMilestonePaymentDescription
One-time $50 million sales milestone payment upon the first attainment of $750 million in net sales of Oxecta across all Pfizer Territories.
acur Royalty Payment Obligation Expiration Description
RoyaltyPaymentObligationExpirationDescription
15 years from the first commercial sale of Oxecta in such country.
CY2012 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
40000 USD
CY2013Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
2300000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1200000 USD
CY2013Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
8800000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6300000 USD
CY2013Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
18900000 USD
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19900000 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
20000000 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
-100000 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD

Files In Submission

Name View Source Status
0001144204-13-042470-index-headers.html Edgar Link pending
0001144204-13-042470-index.html Edgar Link pending
0001144204-13-042470.txt Edgar Link pending
0001144204-13-042470-xbrl.zip Edgar Link pending
acur-20130630.xml Edgar Link completed
acur-20130630.xsd Edgar Link pending
acur-20130630_cal.xml Edgar Link unprocessable
acur-20130630_def.xml Edgar Link unprocessable
acur-20130630_lab.xml Edgar Link unprocessable
acur-20130630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
v350262_10q.htm Edgar Link pending
v350262_ex31-1.htm Edgar Link pending
v350262_ex31-2.htm Edgar Link pending
v350262_ex32-1.htm Edgar Link pending